(NASDAQ: ASRT) Assertio Holdings's forecast annual revenue growth rate of -3.61% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Assertio Holdings's revenue in 2025 is $137,352,000.On average, 6 Wall Street analysts forecast ASRT's revenue for 2025 to be $10,837,984,996, with the lowest ASRT revenue forecast at $10,283,572,975, and the highest ASRT revenue forecast at $11,273,044,429. On average, 6 Wall Street analysts forecast ASRT's revenue for 2026 to be $10,815,847,016, with the lowest ASRT revenue forecast at $9,478,039,259, and the highest ASRT revenue forecast at $11,709,066,384.
In 2027, ASRT is forecast to generate $12,257,703,279 in revenue, with the lowest revenue forecast at $11,777,405,365 and the highest revenue forecast at $12,618,648,606.